Proton Pump Inhibitors Alter Gut Microbiota by Promoting Oral Microbiota Translocation
abstract
This abstract is available on the publisher's site.
Access this abstract nowProton pump inhibitors (PPIs) have been widely used to treat gastric acid-related diseases. They increase intragastric pH by blocking hydrogen/potassium (H+/K+) ATPases of gastric parietal cells. It is reported that nearly a quarter of adults use a PPI, of which, approximately 25%–70% are prescribed inappropriately. With the extensive use of PPIs, adverse responses have emerged, including an increased risk of intestinal infections, community-acquired pneumonia and impeded absorption of micronutrients. Although the relative risk is low, the high worldwide number of PPIs users means that absolute numbers with side effects are still high. These factors greatly contribute to the insecurity of prescribing physicians and the anxiety of patients.
Click on any of these tags to subscribe to Topic Alerts. Once subscribed, you can get a single, daily email any time PracticeUpdate publishes content on the topics that interest you.
Visit your Preferences and Settings section to Manage All Topic Alerts
Additional Info
Proton pump inhibitors alter gut microbiota by promoting oral microbiota translocation: a prospective interventional study
Gut 2024 Jan 30;[EPub Ahead of Print], X Xiao, X Zhang, J Wang, Y Liu, H Yan, X Xing, J YangFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.